File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo
  • Basic View
  • Metadata View
  • XML View
TitleGold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo
 
AuthorsYuk, FT1
Sun, RWY3 4
Chen, Y1 5
Chan, VSF5 1 2
Yu, WY6 3 4
Tam, PKH1
Che, CM3 4
Lin, CLS1 5
 
KeywordsChemotherapeutics
Cisplatin
Gold(III)
Nasopharyngeal carcinoma
Neoplasm
Porphyrin
 
Issue Date2009
 
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
CitationInternational Journal Of Cancer, 2009, v. 124 n. 8, p. 1971-1979 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.24130
 
AbstractNasopharyngeal carcinoma (NPC) is a common neoplasm in Southeastern Asia, and cisplatin-containing regimens for combinational chemotherapy are widely used for treating locally recurrent or metastatic diseases. However, resistance to cisplatin is not infrequently seen and its associated side effects may be life-threatening. In this report, another metallo-pharmaceutical agent gold(III) porphyrin complex [Au(TPP)]Cl was investigated in comparison to cisplatin for its in vitro and in vivo anticancer effects. Through induction of the intrinsic apoptosis pathway, [Au(TPP)]Cl exhibited 100-fold higher potency than cisplatin in killing NPC cells, including cisplatin-sensitive and cisplatin-resistant variants, and also an variant harboring the Epstein-Barr virus. In addition, a safety concentration window was demonstrated, allowing [Au(TPP)]Cl to kill tumors with minimal cytotoxicity to noncancerous cells. More importantly, weekly intraperitoneal injection of 3 mg/kg [Au(TPP)]Cl was more effective than the same dose of cisplatin in inducing tumor apoptosis in vivo and remarkably inhibited tumor growth in animals without any noticeable side effect. [Au(TPP)]Cl therefore is a promising chemotherapeutic agent that deserves further development as a novel drug for the treatment of advanced NPC, in particular, for cases with cisplatin-resistance. © 2008 Wiley-Liss, Inc.
 
ISSN0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
DOIhttp://dx.doi.org/10.1002/ijc.24130
 
ISI Accession Number IDWOS:000264452700028
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYuk, FT
 
dc.contributor.authorSun, RWY
 
dc.contributor.authorChen, Y
 
dc.contributor.authorChan, VSF
 
dc.contributor.authorYu, WY
 
dc.contributor.authorTam, PKH
 
dc.contributor.authorChe, CM
 
dc.contributor.authorLin, CLS
 
dc.date.accessioned2011-03-28T09:25:20Z
 
dc.date.available2011-03-28T09:25:20Z
 
dc.date.issued2009
 
dc.description.abstractNasopharyngeal carcinoma (NPC) is a common neoplasm in Southeastern Asia, and cisplatin-containing regimens for combinational chemotherapy are widely used for treating locally recurrent or metastatic diseases. However, resistance to cisplatin is not infrequently seen and its associated side effects may be life-threatening. In this report, another metallo-pharmaceutical agent gold(III) porphyrin complex [Au(TPP)]Cl was investigated in comparison to cisplatin for its in vitro and in vivo anticancer effects. Through induction of the intrinsic apoptosis pathway, [Au(TPP)]Cl exhibited 100-fold higher potency than cisplatin in killing NPC cells, including cisplatin-sensitive and cisplatin-resistant variants, and also an variant harboring the Epstein-Barr virus. In addition, a safety concentration window was demonstrated, allowing [Au(TPP)]Cl to kill tumors with minimal cytotoxicity to noncancerous cells. More importantly, weekly intraperitoneal injection of 3 mg/kg [Au(TPP)]Cl was more effective than the same dose of cisplatin in inducing tumor apoptosis in vivo and remarkably inhibited tumor growth in animals without any noticeable side effect. [Au(TPP)]Cl therefore is a promising chemotherapeutic agent that deserves further development as a novel drug for the treatment of advanced NPC, in particular, for cases with cisplatin-resistance. © 2008 Wiley-Liss, Inc.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationInternational Journal Of Cancer, 2009, v. 124 n. 8, p. 1971-1979 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.24130
 
dc.identifier.doihttp://dx.doi.org/10.1002/ijc.24130
 
dc.identifier.eissn1097-0215
 
dc.identifier.epage1979
 
dc.identifier.hkuros155198
 
dc.identifier.isiWOS:000264452700028
 
dc.identifier.issn0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
dc.identifier.issue8
 
dc.identifier.pmid19107930
 
dc.identifier.scopuseid_2-s2.0-62449242847
 
dc.identifier.spage1971
 
dc.identifier.urihttp://hdl.handle.net/10722/132490
 
dc.identifier.volume124
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshAnimals
 
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use
 
dc.subject.meshCarcinoma - drug therapy
 
dc.subject.meshCell Differentiation
 
dc.subject.meshCell Line, Tumor
 
dc.subject.meshCisplatin - therapeutic use
 
dc.subject.meshFemale
 
dc.subject.meshGold - administration & dosage
 
dc.subject.meshHumans
 
dc.subject.meshMice
 
dc.subject.meshMice, Inbred BALB C
 
dc.subject.meshModels, Chemical
 
dc.subject.meshNasopharyngeal Neoplasms - drug therapy
 
dc.subject.meshPorphyrins - administration & dosage
 
dc.subject.meshTreatment Outcome
 
dc.subjectChemotherapeutics
 
dc.subjectCisplatin
 
dc.subjectGold(III)
 
dc.subjectNasopharyngeal carcinoma
 
dc.subjectNeoplasm
 
dc.subjectPorphyrin
 
dc.titleGold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yuk, FT</contributor.author>
<contributor.author>Sun, RWY</contributor.author>
<contributor.author>Chen, Y</contributor.author>
<contributor.author>Chan, VSF</contributor.author>
<contributor.author>Yu, WY</contributor.author>
<contributor.author>Tam, PKH</contributor.author>
<contributor.author>Che, CM</contributor.author>
<contributor.author>Lin, CLS</contributor.author>
<date.accessioned>2011-03-28T09:25:20Z</date.accessioned>
<date.available>2011-03-28T09:25:20Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>International Journal Of Cancer, 2009, v. 124 n. 8, p. 1971-1979</identifier.citation>
<identifier.issn>0020-7136</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/132490</identifier.uri>
<description.abstract>Nasopharyngeal carcinoma (NPC) is a common neoplasm in Southeastern Asia, and cisplatin-containing regimens for combinational chemotherapy are widely used for treating locally recurrent or metastatic diseases. However, resistance to cisplatin is not infrequently seen and its associated side effects may be life-threatening. In this report, another metallo-pharmaceutical agent gold(III) porphyrin complex [Au(TPP)]Cl was investigated in comparison to cisplatin for its in vitro and in vivo anticancer effects. Through induction of the intrinsic apoptosis pathway, [Au(TPP)]Cl exhibited 100-fold higher potency than cisplatin in killing NPC cells, including cisplatin-sensitive and cisplatin-resistant variants, and also an variant harboring the Epstein-Barr virus. In addition, a safety concentration window was demonstrated, allowing [Au(TPP)]Cl to kill tumors with minimal cytotoxicity to noncancerous cells. More importantly, weekly intraperitoneal injection of 3 mg/kg [Au(TPP)]Cl was more effective than the same dose of cisplatin in inducing tumor apoptosis in vivo and remarkably inhibited tumor growth in animals without any noticeable side effect. [Au(TPP)]Cl therefore is a promising chemotherapeutic agent that deserves further development as a novel drug for the treatment of advanced NPC, in particular, for cases with cisplatin-resistance. &#169; 2008 Wiley-Liss, Inc.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc.. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/journal/29331/home</publisher>
<relation.ispartof>International Journal of Cancer</relation.ispartof>
<rights>International Journal of Cancer. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>Chemotherapeutics</subject>
<subject>Cisplatin</subject>
<subject>Gold(III)</subject>
<subject>Nasopharyngeal carcinoma</subject>
<subject>Neoplasm</subject>
<subject>Porphyrin</subject>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject.mesh>
<subject.mesh>Carcinoma - drug therapy</subject.mesh>
<subject.mesh>Cell Differentiation</subject.mesh>
<subject.mesh>Cell Line, Tumor</subject.mesh>
<subject.mesh>Cisplatin - therapeutic use</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Gold - administration &amp; dosage</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Mice</subject.mesh>
<subject.mesh>Mice, Inbred BALB C</subject.mesh>
<subject.mesh>Models, Chemical</subject.mesh>
<subject.mesh>Nasopharyngeal Neoplasms - drug therapy</subject.mesh>
<subject.mesh>Porphyrins - administration &amp; dosage</subject.mesh>
<subject.mesh>Treatment Outcome</subject.mesh>
<title>Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1002/ijc.24130</identifier.doi>
<identifier.pmid>19107930</identifier.pmid>
<identifier.scopus>eid_2-s2.0-62449242847</identifier.scopus>
<identifier.hkuros>155198</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-62449242847&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>124</identifier.volume>
<identifier.issue>8</identifier.issue>
<identifier.spage>1971</identifier.spage>
<identifier.epage>1979</identifier.epage>
<identifier.eissn>1097-0215</identifier.eissn>
<identifier.isi>WOS:000264452700028</identifier.isi>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/132490/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. Hammersmith Hospital
  3. The University of Hong Kong
  4. Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong
  5. Imperial College London
  6. Hong Kong Polytechnic University